Trial Information

Summary: A Phase III, Flexible-Dose Titration Followed by a Randomized, Double-Blind Study of Controlled-Release OROS Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients with Osteoarthritis Pain.

Researchers want to find out if an investigational drug can help with osteoarthritis pain of the knee or hip.

Patient Inclusion Criteria

• Male or female age 30-80
• Primary Diagnosis of OA of knee or hip joint for at least 6 months
• Patients who require daily opioid analgesics.
• (Other criteria apply)

Patient Exclusion Criteria

• Patients with moderate-to-severe pain caused by disease other than OA.
• Joint replacement at index joint.
• Diagnosis of fibromyalgia or low back pain.
• (Other criteria apply)

If you would like to learn more about participating in this study, please send an e-mail message using the form below.